• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

地诺单抗治疗在骨巨细胞瘤管理中的整合应用。

Integration of denosumab therapy in the management of giant cell tumors of bone.

作者信息

Miles Daniel T, Voskuil Ryan T, Dale Wood, Mayerson Joel L, Scharschmidt Thomas J

机构信息

Department of Orthopaedic Surgery, University of Tennessee College of Medicine Chattanooga, USA.

Division of Musculoskeletal Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, USA.

出版信息

J Orthop. 2020 Mar 28;22:38-47. doi: 10.1016/j.jor.2020.03.020. eCollection 2020 Nov-Dec.

DOI:10.1016/j.jor.2020.03.020
PMID:32280167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7136643/
Abstract

A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.

摘要

文献综述表明，地诺单抗在肿瘤学界越来越受到青睐，尤其是在骨巨细胞瘤（GCTB）中的使用频率不断增加。地诺单抗会成为GCTB治疗的突破吗？在此，我们提供一个相关病例实例，回顾关于地诺单抗用于GCTB的历史和基础科学的文献，强调治疗剂量和疗程的最新见解，并指出该领域的进展。

相似文献

1
Integration of denosumab therapy in the management of giant cell tumors of bone.地诺单抗治疗在骨巨细胞瘤管理中的整合应用。
J Orthop. 2020 Mar 28;22:38-47. doi: 10.1016/j.jor.2020.03.020. eCollection 2020 Nov-Dec.
2
Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.术前地诺单抗联合手术治疗骨巨细胞瘤：一项全面的叙述性文献综述
Gulf J Oncolog. 2019 May;1(30):67-75.
3
Recommencement of Denosumab for Unresectable Giant Cell Tumor of the Cervical Spine: A Case Report.重新开始使用地舒单抗治疗不可切除的颈椎巨细胞瘤：病例报告。
Spine (Phila Pa 1976). 2018 May 1;43(9):E551-E556. doi: 10.1097/BRS.0000000000002440.
4
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.地舒单抗可诱导骨巨细胞瘤患者肿瘤缩小和骨形成。
Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578. Epub 2012 Jun 18.
5
Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.地诺单抗治疗的骨巨细胞瘤（GCTB）的临床病理及分子特征：21例分析
Ann Diagn Pathol. 2022 Apr;57:151882. doi: 10.1016/j.anndiagpath.2021.151882. Epub 2021 Dec 23.
6
Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.重新挑战不可切除骨巨细胞瘤患者颌骨骨坏死中的地舒单抗：病例系列分析和文献复习。
ESMO Open. 2020 Jul;5(4). doi: 10.1136/esmoopen-2019-000663.
7
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.地诺单抗治疗骨巨细胞瘤：基于病理生理机制和真实世界证据的多学科医学管理
Cancers (Basel). 2022 May 4;14(9):2290. doi: 10.3390/cancers14092290.
8
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.术前 denosumab 治疗联合刮除术可能是骨巨细胞瘤复发的一个危险因素。
J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020929786. doi: 10.1177/2309499020929786.
9
Updated concepts in treatment of giant cell tumor of bone.骨巨细胞瘤治疗的新概念。
Curr Opin Oncol. 2022 Jul 1;34(4):371-378. doi: 10.1097/CCO.0000000000000852.
10
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone.地诺单抗治疗不可手术切除或局部晚期骨巨细胞瘤。
Oncol Lett. 2016 Dec;12(6):4312-4318. doi: 10.3892/ol.2016.5246. Epub 2016 Oct 12.

引用本文的文献

1
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.地诺单抗治疗骨巨细胞瘤：基于病理生理机制和真实世界证据的多学科医学管理
Cancers (Basel). 2022 May 4;14(9):2290. doi: 10.3390/cancers14092290.
2
New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.新一代的孕激素拮抗剂（SPRMs）进入骨质疏松症的治疗方法。
Molecules. 2021 Oct 27;26(21):6491. doi: 10.3390/molecules26216491.
3
A giant cell tumor of the bone in the rib cage left to proliferate unfettered for seven years to an extensive size.一名位于左侧胸廓的骨巨细胞瘤未经治疗持续增殖了七年，发展至体积巨大。
Respir Med Case Rep. 2021 May 1;33:101419. doi: 10.1016/j.rmcr.2021.101419. eCollection 2021.
4
A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva) Related Osteonecrosis of the Jaw: A Retrospective Study.地诺单抗（Xgeva）相关颌骨坏死的临床与影像学范围比较：一项回顾性研究
J Clin Med. 2021 May 28;10(11):2390. doi: 10.3390/jcm10112390.
5
The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone.地诺单抗在骨巨细胞瘤所致急性病理性骨折中的应用。
World J Surg Oncol. 2021 Feb 2;19(1):37. doi: 10.1186/s12957-021-02143-3.

本文引用的文献

1
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.骨巨细胞瘤中的组蛋白H3.3突变：病理学新进展
Med Mol Morphol. 2020 Mar;53(1):1-6. doi: 10.1007/s00795-019-00238-1. Epub 2019 Nov 20.
2
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.地舒单抗治疗骨巨细胞瘤患者的多中心、开放标签、2 期研究。
Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6.
3
The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics.骨保护素在血管钙化和骨代谢中的作用：开发新疗法的基础。
Calcif Tissue Int. 2019 Sep;105(3):239-251. doi: 10.1007/s00223-019-00573-6. Epub 2019 Jun 13.
4
Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?地诺单抗治疗骨盆和骶骨骨巨细胞瘤：长期治疗还是骨切除术？
J Orthop Sci. 2020 May;25(3):513-519. doi: 10.1016/j.jos.2019.05.003. Epub 2019 May 30.
5
Bone metastasis: Interaction between cancer cells and bone microenvironment.骨转移：癌细胞与骨微环境之间的相互作用。
J Oral Biosci. 2019 Jun;61(2):95-98. doi: 10.1016/j.job.2019.02.002. Epub 2019 Mar 5.
6
Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.辅助唑来膦酸治疗高危骨巨细胞瘤：一项多中心随机 II 期试验。
Oncologist. 2019 Jul;24(7):889-e421. doi: 10.1634/theoncologist.2019-0280. Epub 2019 Apr 30.
7
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.骨巨细胞瘤刮除术前地诺单抗的随机III期试验：日本临床肿瘤学组研究JCOG1610
Jpn J Clin Oncol. 2019 Apr 1;49(4):379-382. doi: 10.1093/jjco/hyz004.
8
Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?术前地舒单抗联合刮除术和冷冻疗法治疗骨巨细胞瘤：局部复发风险是否增加？
Clin Orthop Relat Res. 2018 Sep;476(9):1783-1790. doi: 10.1007/s11999.0000000000000104.
9
Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.新辅助地舒单抗：其在可手术治疗的骨巨细胞瘤中的作用和结果。
Bone Joint J. 2019 Feb;101-B(2):170-177. doi: 10.1302/0301-620X.101B2.BJJ-2018-0907.R2.
10
Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.地舒单抗可能增加骨巨细胞瘤患者经刮除治疗后的局部复发风险。
J Bone Joint Surg Am. 2018 Mar 21;100(6):496-504. doi: 10.2106/JBJS.17.00057.